Examining the Effects of Bright Light Therapy on Sleep and Resting-State Brain Activity in Parkinson's Disease: A Randomized Crossover Pilot Study
Abstract
Purpose: Sleep disturbances are highly prevalent in patients with Parkinson's disease (PD). Bright light therapy (BLT) seems to be a promising non-pharmacological intervention for sleep disturbance in PD. However, the neural mechanisms underlying BLT remain unclear. In this pilot study, we aimed to explore the clinical effects of BLT on sleep and to explore potential accompanying changes in brain activity and functional connectivity.
Patients and methods: In this randomized, crossover, self-controlled pilot study, BLT was delivered using bright light at 10,000 lux, and dim light at 200 lux served as the control condition. Twenty-seven patients with PD were assigned to receive 30 days of BLT and 30 days of dim light therapy (DLT) in counterbalanced order, separated by a 30-day washout period. Clinical assessments of sleep, polysomnography (PSG) and resting-state functional magnetic resonance imaging (rs-fMRI) were performed at four time points: baseline, following the first intervention phase, following the washout period, and following the second intervention phase.
Results: Compared with DLT, BLT was associated with a significantly greater reduction in Epworth Sleepiness Scale (ESS) scores (P=0.012) and tonic REM sleep without atonia (RWA) (P=0.002). In resting-state fMRI, no clusters showed significant alterations in fractional amplitude of low-frequency fluctuation (fALFF) or dynamic fALFF (dfALFF) after BLT compared to DLT. Functional connectivity (FC) analyses using the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.